Epigenetic Suppression of the TGF-beta Pathway Revealed by Transcriptome Profiling in Ovarian Cancer
Overview
Authors
Affiliations
Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies. Diagnosis usually occurs after metastatic spread, largely reflecting vague symptoms of early disease combined with lack of an effective screening strategy. Epigenetic mechanisms of gene regulation, including DNA methylation, are fundamental to normal cellular function and also play a major role in carcinogenesis. To elucidate the biological and clinical relevance of DNA methylation in ovarian cancer, we conducted expression microarray analysis of 39 cell lines and 17 primary culture specimens grown in the presence or absence of DNA methyltransferase (DNMT) inhibitors. Two parameters, induction of expression and standard deviation among untreated samples, identified 378 candidate methylated genes, many relevant to TGF-beta signaling. We analyzed 43 of these genes and they all exhibited methylation. Treatment with DNMT inhibitors increased TGF-beta pathway activity. Hierarchical clustering of ovarian cancers using the 378 genes reproducibly generated a distinct gene cluster strongly correlated with TGF-beta pathway activity that discriminates patients based on age. These data suggest that accumulation of age-related epigenetic modifications leads to suppression of TGF-beta signaling and contributes to ovarian carcinogenesis.
Lee D, Park E, Kim J, Shin H, Lee Y, Jeong H Genes Genomics. 2024; 46(11):1313-1325.
PMID: 39215947 DOI: 10.1007/s13258-024-01547-1.
Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer.
Bai Y, Li L, Li J, Lu X Heliyon. 2024; 10(9):e30727.
PMID: 38774095 PMC: 11107115. DOI: 10.1016/j.heliyon.2024.e30727.
Current data and future perspectives on DNA methylation in ovarian cancer (Review).
Fu M, Deng F, Chen J, Fu L, Lei J, Xu T Int J Oncol. 2024; 64(6).
PMID: 38757340 PMC: 11095605. DOI: 10.3892/ijo.2024.5650.
Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W, Tyner J, Gery S, Zheng Y, Li L, Gopinatha Pillai M J Ovarian Res. 2023; 16(1):80.
PMID: 37087441 PMC: 10122390. DOI: 10.1186/s13048-023-01160-y.
Visco Z, Sfakianos G, Grenier C, Boudreau M, Simpson S, Rodriguez I Front Oncol. 2021; 11:620873.
PMID: 33828978 PMC: 8019902. DOI: 10.3389/fonc.2021.620873.